On November 13, 2013, the China Food and Drug Administration (CFDA) published a draft amendment to the Drug Registration Regulation (“DRR”) for public comment by December 13, 2013. The draft amendment is significant to both Chinese domestic pharmaceutical companies and multinational pharma companies operating in China because it reflects CFDA’s current thinking on critical issues involving regulatory approval for pharmaceutical and biological products.
You are invited to join this webinar which will discuss the implications of this major amendment and its potential impact. Chen Yang, Head of Sidley’s China Life Sciences Practice and Dr. Ling Su, Life Sciences Strategic Advisor at Sidley, and Immediate Past President of DIA, will lead the discussion.
Tuesday, November 26th, 2013
10:00 - 11:00am EST / 3:00 - 4:00pm GMT / 11:00pm - 12:00am CST
For more information or questions, please contact us at email@example.com.